BioAtla, Inc. (NASDAQ:BCAB) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET

Company Participants

Bruce Mackle - LifeSci Advisors, IR
Dr. Jay Short - Chairman, Co-Founder and CEO
Richard Waldron - Chief Financial Officer
Dr. Eric Sievers - Chief Medical Officer
Sheri Lydick - Chief Commercial Officer

Conference Call Participants

Brian Cheng - JPMorgan
Arthur He - H.C. Wainwright

Operator

Good day, everyone. And welcome to today’s BioAtla Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions]

I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Bruce Mackle of LifeSci Advisors.

Bruce Mackle

Thank you, Operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; and Richard Waldron, Chief Financial Officer. Following today’s call, Dr. Eric Sievers, Chief Medical Officer; and Sheri Lydick, Chief Commercial Officer, will join Jay and Rick in a short Q&A.

Earlier this afternoon, BioAtla released financial results and a business update for the second quarter ended June 30, 2024. A copy of the press release and corporate presentation are available on the company’s website.

Before we begin, I’d like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtla’s business plans and prospects and whether its clinical trials will support registration, plans to form collaborations and other strategic partnerships for selected assets, achievement of milestones, results, conduct, progress, and timing of its research and development programs and clinical trials, expectations with respect to enrollment and dosing in its clinical trials, plans and expectations regarding future data updates, clinical trials, regulatory meetings, and regulatory submissions, the potential regulatory approval path for its product candidates, expectations about the sufficiency of its cash and cash equivalents to fund operations, and expectations regarding R&D expense and cash burn.

These statements are subject to various risks, assumptions and uncertainties that can cause actual results to differ materially and are described in the filings made with the SEC, including the most recent quarterly report on Form 10-Q.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, August 8, 2024, and BioAtla disclaims any obligation to update such statements to reflect future information, events or circumstances, except as required by law.